Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

PURPOSE: Panobinostat is partly metabolized by CYP3A4 in vitro. This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat. METHODS: Patients received a single panobinostat oral dose on day 1, followed by 4 days wash-out period. On d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamberg, Paul, Woo, Margaret M., Chen, Lin-Chi, Verweij, Jaap, Porro, Maria Grazia, Zhao, Lily, Li, Wenkui, van der Biessen, Diane, Sharma, Sunil, Hengelage, Thomas, de Jonge, Maja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162150/
https://www.ncbi.nlm.nih.gov/pubmed/21706316
http://dx.doi.org/10.1007/s00280-011-1693-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162150/
https://www.ncbi.nlm.nih.gov/pubmed/21706316
http://dx.doi.org/10.1007/s00280-011-1693-x

Ejemplares similares